Adenosine Deaminase Enzyme Therapy Prevents and Reverses the Heightened Cavernosal Relaxation in Priapism

Journal of Sexual Medicine

Volumn 7, Issue 9, 2010, Pages 3011-3022

  Wen, Jiaming ^a,b   Jiang, Xianzhen ^b   Dai, Yingbo ^b   Zhang, Yujin ^a,b   Tang, Yuxin ^b   Sun, Hong ^b   Mi, Tiejuan ^a   Kellems, Rodney E ^a   Blackburn, Michael R ^a   Xia, Yang ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Adenosine signaling; Novel therapies; Pharmacologic treatment of priapism; Priapism

Indexed keywords

ADENOSINE; ADENOSINE DEAMINASE; MACROGOL;

ADENOSINE DEAMINASE DEFICIENCY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS CAVERNOSUM; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; ELECTROSTIMULATION; ENZYME THERAPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PENIS; PRIAPISM; PRIORITY JOURNAL; SICKLE CELL ANEMIA; SMOOTH MUSCLE RELAXATION; TRANSGENIC MOUSE;

EID: 77956277664     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2009.01552.x     Document Type: Article

References (61)

1. Burnett AL. Priapism pathophysiology: Clues to prevention. Int J Impot Res 2003, 15(5):S80-5. suppl
2. Burnett AL. Therapy insight: Priapism associated with hematologic dyscrasias. Nat Clin Pract Urol 2005, 2:449-56.
3. Eland IA, van der Lei J, Stricker BH, Sturkenboom MJ. Incidence of priapism in the general population. Urology 2001, 57:970-2.
4. Diggs LaC RE. Pathology of sickle cell anemia. South Med J 1934, 27:839-45.
5. Fowler JE, Koshy M, Strub M, Chinn SK. Priapism associated with the sickle cell hemoglobinopathies: Prevalence, natural history and sequelae. J Urol 1991, 145:65-8.
6. Mantadakis E, Cavender JD, Rogers ZR, Ewalt DH, Buchanan GR. Prevalence of priapism in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol 1999, 21:518-22.
7. Adeyoju AB, Olujohungbe AB, Morris J, Yardumian A, Bareford D, Akenova A, Akinyanju O, Cinkotai K, O'Reilly PH. Priapism in sickle-cell disease; incidence, risk factors and complications-an international multicentre study. BJU Int 2002, 90:898-902.
8. Burnett AL. Erectile dysfunction. J Urol 2006, 175:S25-31.
9. Burnett AL. Erectile dysfunction: A practical approach for primary care. Geriatrics 1998, 53:46-8.
10. Burnett AL, Allen RP, Tempany CM, Dover GJ, Brendler CB. Evaluation of erectile function in men with sickle cell disease. Urology 1995, 45:657-63.
11. Bochinski DJ, Dean RC, Lue TF. Erectile dysfunction and priapism. Nat Clin Pract Urol 2004, 1:49-53.
12. Burnett AL, Lowenstein CJ, Bredt DS, Chang TS, Snyder SH. Nitric oxide: A physiologic mediator of penile erection. Science 1992, 257:401-3.
13. Lue TF. Erectile dysfunction. N Engl J Med 2000, 342:1802-13.
14. Champion HC, Bivalacqua TJ, Takimoto E, Kass DA, Burnett AL. Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci U S A 2005, 102:1661-6.
15. Jin YC, Gam SC, Jung JH, Hyun JS, Chang KC, Hyun JS. Expression and activity of heme oxygenase-1 in artificially induced low-flow priapism in rat penile tissues. J Sex Med 2008, 5:1876-82.
16. Shamloul R. The potential role of the heme oxygenase/carbon monoxide system in male sexual dysfunctions. J Sex Med 2009, 6:324-33.
17. Fredholm BB. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ 2007, 14:1315-23.
18. Chiang PH, Wu SN, Tsai EM, Wu CC, Shen MR, Huang CH, Chiang CP. Adenosine modulation of neurotransmission in penile erection. Br J Clin Pharmacol 1994, 38:357-62.
19. Filippi S, Mancini M, Amerini S, Bartolini M, Natali A, Mancina R, Forti G, Ledda F, Maggi M. Functional adenosine receptors in human corpora cavernosa. Int J Androl 2000, 23:210-7.
20. Tostes RC, Giachini FR, Carneiro FS, Leite R, Inscho EW, Webb RC. Determination of adenosine effects and adenosine receptors in murine corpus cavernosum. J Pharmacol Exp Ther 2007, 322:678-85.
21. Kilic S, Salih M, Anafarta K, Baltaci S, Kosar A. Adenosine: A new agent in the diagnosis of impotence. Int J Impot Res 1994, 6:191-8.
22. Yonezawa A, Sakurada S, Furukawa K, Kimura Y. Adenosine and adenosine triphosphate. Nippon Rinsho 2002, 60(6):52-6. suppl
23. Noto T, Inoue H, Mochida H, Kikkawa K. Role of adenosine and P2 receptors in the penile tumescence in anesthetized dogs. Eur J Pharmacol 2001, 425:51-5.
24. Sharifzadeh M, Zarrindast MR, Samini M. Effects of adenosine analogues on apomorphine-induced penile erection in rats. Gen Pharmacol 1995, 26:1785-90.
25. Faria M, Magalhaes-Cardoso T, Lafuente-de-Carvalho J-M, Correia-de-Sa P. Corpus cavernosum from men with vasculogenic impotence is partially resistant to adenosine relaxation due to endothelial A2B receptor dysfunction. J Pharmacol Exp Ther 2006, 319:405-13. 10.1124/jpet.106.107821
26. Mi T, Abbasi S, Zhang H, Uray K, Chunn JL, Xia LW, Molina JG, Weisbrodt NW, Kellems RE, Blackburn MR, Xia Y. Excess adenosine in murine penile erectile tissues contributes to priapism via A2B adenosine receptor signaling. J Clin Invest 2008, 118:1491-501.
27. Bivalacqua TJ, Musicki B, Hsu LL, Gladwin MT, Burnett AL, Champion HC. Establishment of a transgenic sickle-cell mouse model to study the pathophysiology of priapism. J Sex Med 2009, 6:2494-504.
28. Claudino MA, Franco-Penteado CF, Corat MA, Gimenes AP, Passos LA, Antunes E, Costa FF. Increased cavernosal relaxations in sickle cell mice priapism are associated with alterations in the no-cGMP signaling pathway. J Sex Med 2009, 6:2187-96.
29. Paszty C. Transgenic and gene knock-out mouse models of sickle cell anemia and the thalassemias. Curr Opin Hematol 1997, 4:88-93.
30. Pászty C, Brion CM, Manci E, Witkowska HE, Stevens ME, Mohandas N, Rubin EM. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science (NY) 1997, 278:876-8.
31. Ryan TM, Ciavatta DJ, Townes TM. Knockout-transgenic mouse model of sickle cell disease. Science 1997, 278:873-6.
32. Blackburn MR, Aldrich M, Volmer JB, Chen W, Zhong H, Kelly S, Hershfield MS, Datta SK, Kellems RE. The use of enzyme therapy to regulate the metabolic and phenotypic consequences of adenosine deaminase deficiency in mice. Differential impact on pulmonary and immunologic abnormalities. J Biol Chem 2000, 275:32114-21.
33. Blackburn MR, Kellems RE. Adenosine deaminase deficiency: Metabolic basis of immune deficiency and pulmonary inflammation. Adv Immunol 2005, 86:1-41.
34. Hershfield MS. PEG-ADA replacement therapy for adenosine deaminase deficiency: An update after 8.5 years. Clin Immunol Immunopathol 1995, 76:S228-32.
35. Hershfield MS, Chaffee S, Sorensen RU. Enzyme replacement therapy with polyethylene glycol-adenosine deaminase in adenosine deaminase deficiency: Overview and case reports of three patients, including two now receiving gene therapy. Pediatr Res 1993, 33:S47-8.
36. Blackburn MR, Datta SK, Kellems RE. Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency. J Biol Chem 1998, 273:5093-100.
37. Blackburn MR, Datta SK, Wakamiya M, Vartabedian BS, Kellems RE. Metabolic and immunologic consequences of limited adenosine deaminase expression in mice. J Biol Chem 1996, 271:15203-10.
38. Chunn JL, Mohsenin A, Young HW, Lee CG, Elias JA, Kellems RE, Blackburn MR. Partially adenosine deaminase-deficient mice develop pulmonary fibrosis in association with adenosine elevations. Am J Physiol 2006, 290:L579-87.
39. Chunn JL, Molina JG, Mi T, Xia Y, Kellems RE, Blackburn MR. Adenosine-dependent pulmonary fibrosis in adenosine deaminase-deficient mice. J Immunol 2005, 175:1937-46.
40. Chunn JL, Young HW, Banerjee SK, Colasurdo GN, Blackburn MR. Adenosine-dependent airway inflammation and hyperresponsiveness in partially adenosine deaminase-deficient mice. J Immunol 2001, 167:4676-85.
41. Hedlund P, Aszodi A, Pfeifer A, Alm P, Hofmann F, Ahmad M, Fassler R, Andersson KE. Erectile dysfunction in cyclic GMP-dependent kinase I-deficient mice. Proc Natl Acad Sci U S A 2000, 97:2349-54.
42. Muneer A, Cellek S, Dogan A, Kell PD, Ralph DJ, Minhas S. Investigation of cavernosal smooth muscle dysfunction in low flow priapism using an in vitro model. Int J Impot Res 2005, 17:10-8.
43. Werner ME, Zvara P, Meredith AL, Aldrich RW, Nelson MT. Erectile dysfunction in mice lacking the large-conductance calcium-activated potassium (BK) channel. J Physiol 2005, 567:545-56.
44. Dai Y, Zhang Y, Phatarpekar P, Mi T, Zhang H, Blackburn MR, Xia Y. Adenosine signaling, priapism and novel therapies. J Sex Med 2009, 6(3):292-301. suppl
45. Filippi S, Amerini S, Maggi M, Natali A, Ledda F. Studies on the mechanisms involved in the ATP-induced relaxation in human and rabbit corpus cavernosum. J Urol 1999, 161:326-31.
46. Pryor J, Akkus E, Alter G, Jordan G, Lebret T, Levine L, Mulhall J, Perovic S, Ralph D, Stackl W. Priapism. J Sex Med 2004, 1:116-20.
47. Bennett N, Mulhall J. Sickle cell disease status and outcomes of African-American men presenting with priapism. J Sex Med 2008, 5:1244-50.
48. Jin YC, Gam SC, Jung JH, Hyun JS, Chang KC, Hyun JS. Expression and activity of heme oxygenase-1 in artificially induced low-flow priapism in rat penile tissues. 2008, 5:1876-82.
49. Munarriz R, Wen CC, McAuley I, Goldstein I, Traish A, Kim N. Management of ischemic priapism with high-dose intracavernosal phenylephrine: From bench to bedside. J Sex Med 2006, 3:918-22.
50. Lin CS, Lin G, Lue TF. Cyclic nucleotide signaling in cavernous smooth muscle. J Sex Med 2005, 2:478-91.
51. Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism. J Sex Med 2006, 3:1077-84.
52. Rachid-Filho D, Cavalcanti AG, Favorito LA, Costa WS, Sampaio FJ. Treatment of recurrent priapism in sickle cell anemia with finasteride: A new approach. Urology 2009, Jul 16. [Epub ahead of print] doi:10.1016/j.urology.2009.04.071
53. Tzortzis V, Mitrakas L, Gravas S, Mamoulakis C, Meissner A, Kyriakou D, Melekos MD. Oral phosphodiesterase type 5 inhibitors alleviate recurrent priapism complicating thalassemia intermedia: A case report. J Sex Med 2009, 6:2068-71.
54. Burnett AL, Bivalacqua TJ. Glucose-6-phosphate dehydrogenase deficiency: An etiology for idiopathic priapism? J Sex Med 2008, 5:237-40.
55. Carneiro FS, Giachini FR, Lima VV, Carneiro ZN, Leite R, Inscho EW, Tostes RC, Webb RC. Adenosine actions are preserved in corpus cavernosum from obese and type II diabetic db/db mouse. J Sex Med 2008, 5:1156-66.
56. Takahashi Y, Ishii N, Lue TF, Tanagho EA. Pharmacological effects of adenosine on canine penile erection. Tohoku J Exp Med 1991, 165:49-58.
57. Tostes RC, Giachini FR, Carneiro FS, Leite R, Inscho EW, Webb RC. Determination of adenosine effects and adenosine receptors in murine corpus cavernosum. J Pharmacol Exp Ther 2007, 322:678-85.
58. Faria M, Magalhaes-Cardoso T, Lafuente-de-Carvalho JM, Correia-de-Sa P. Corpus cavernosum from men with vasculogenic impotence is partially resistant to adenosine relaxation due to endothelial A(2B) receptor dysfunction. J Pharmacol Exp Ther 2006, 319:405-13.
59. Booth C, Hershfield M, Notarangelo L, Buckley R, Hoenig M, Mahlaoui N, Cavazzana-Calvo M, Aiuti A, Gaspar HB. Management options for adenosine deaminase deficiency; proceedings of the EBMT satellite workshop (Hamburg, March 2006). Clin Immunol 2007, 123:139-47.
60. Chan B, Wara D, Bastian J, Hershfield MS, Bohnsack J, Azen CG, Parkman R, Weinberg K, Kohn DB. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). Clin Immunol 2005, 117:133-43.
61. Hershfield MS. PEG-ADA: An alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency. Hum Mutat 1995, 5:107-12.